Clinical assessment of lower extremity peripheral arterial disease: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Congestive heart failure}} {{CMG}} {{AE}} {{USAMA}} =2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease = ===Re...")
 
No edit summary
Line 18: Line 18:
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''3.''' Patients with PAD should undergo noninvasive blood pressure measurement in both arms at least once during the initial assessment''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: BNR]])''<nowiki>"</nowiki>
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''3.''' Patients with PAD should undergo noninvasive blood pressure measurement in both arms at least once during the initial assessment''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: BNR]])''<nowiki>"</nowiki>
|-
|-
|}
{| class="wikitable"
!Patients at Increased Risk of PAD
|-
|
* Age ≥65 y
* Age 50–64 y, with risk factors for atherosclerosis (e.g., diabetes mellitus, history of smoking,  hyperlipidemia, hypertension) or family history of PAD
* Age <50 y, with diabetes mellitus and 1 additional risk factor for atherosclerosis
* Individuals with known atherosclerotic disease in another vascular bed (e.g., coronary, carotid,  subclavian, renal, mesenteric artery stenosis, or AAA)
|}
|}

Revision as of 17:27, 17 November 2016


Congestive Heart Failure Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Systolic Dysfunction
Diastolic Dysfunction
HFpEF
HFrEF

Causes

Differentiating Congestive heart failure from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Clinical Assessment

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Cardiac MRI

Echocardiography

Exercise Stress Test

Myocardial Viability Studies

Cardiac Catheterization

Other Imaging Studies

Other Diagnostic Studies

Treatment

Invasive Hemodynamic Monitoring

Medical Therapy:

Summary
Acute Pharmacotherapy
Chronic Pharmacotherapy in HFpEF
Chronic Pharmacotherapy in HFrEF
Diuretics
ACE Inhibitors
Angiotensin receptor blockers
Aldosterone Antagonists
Beta Blockers
Ca Channel Blockers
Nitrates
Hydralazine
Positive Inotropics
Anticoagulants
Angiotensin Receptor-Neprilysin Inhibitor
Antiarrhythmic Drugs
Nutritional Supplements
Hormonal Therapies
Drugs to Avoid
Drug Interactions
Treatment of underlying causes
Associated conditions

Exercise Training

Surgical Therapy:

Biventricular Pacing or Cardiac Resynchronization Therapy (CRT)
Implantation of Intracardiac Defibrillator
Ultrafiltration
Cardiac Surgery
Left Ventricular Assist Devices (LVADs)
Cardiac Transplantation

ACC/AHA Guideline Recommendations

Initial and Serial Evaluation of the HF Patient
Hospitalized Patient
Patients With a Prior MI
Sudden Cardiac Death Prevention
Surgical/Percutaneous/Transcather Interventional Treatments of HF
Patients at high risk for developing heart failure (Stage A)
Patients with cardiac structural abnormalities or remodeling who have not developed heart failure symptoms (Stage B)
Patients with current or prior symptoms of heart failure (Stage C)
Patients with refractory end-stage heart failure (Stage D)
Coordinating Care for Patients With Chronic HF
Quality Metrics/Performance Measures

Implementation of Practice Guidelines

Congestive heart failure end-of-life considerations

Specific Groups:

Special Populations
Patients who have concomitant disorders
Obstructive Sleep Apnea in the Patient with CHF
NSTEMI with Heart Failure and Cardiogenic Shock

Clinical assessment of lower extremity peripheral arterial disease On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Clinical assessment of lower extremity peripheral arterial disease

CDC on Clinical assessment of lower extremity peripheral arterial disease

Clinical assessment of lower extremity peripheral arterial disease in the news

Blogs on Clinical assessment of lower extremity peripheral arterial disease

Directions to Hospitals Treating Clinical assessment of lower extremity peripheral arterial disease

Risk calculators and risk factors for Clinical assessment of lower extremity peripheral arterial disease

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Usama Talib, BSc, MD [2]

2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease

Recommendations for History and Presentation

Class I
"1. Patients at increased risk of PAD ( (Table 1) should undergo a comprehensive medical history and a review of symptoms to assess for exertional leg symptoms, including claudication or other walking impairment, ischemic rest pain, and nonhealing wounds(Level of Evidence: BNR)"
"2. Patients at increased risk of PAD (Table 1) should undergo vascular examination, including palpation of lower extremity pulses (i.e., femoral, popliteal, dorsalis pedis, and posterior tibial), auscultation for femoral bruits, and inspection of the legs and feet(Level of Evidence: BNR)"
"3. Patients with PAD should undergo noninvasive blood pressure measurement in both arms at least once during the initial assessment(Level of Evidence: BNR)"
Patients at Increased Risk of PAD
  • Age ≥65 y
  • Age 50–64 y, with risk factors for atherosclerosis (e.g., diabetes mellitus, history of smoking, hyperlipidemia, hypertension) or family history of PAD
  • Age <50 y, with diabetes mellitus and 1 additional risk factor for atherosclerosis
  • Individuals with known atherosclerotic disease in another vascular bed (e.g., coronary, carotid, subclavian, renal, mesenteric artery stenosis, or AAA)